Literature DB >> 31024089

Past, present and future perspectives in nonalcoholic fatty liver disease.

Arun J Sanyal1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) was first described as a distinct clinical entity four decades ago. However, the condition has become the centre of attention within hepatology owing to its high prevalence and growing contribution to the burden of end-stage liver disease in the general population. This Perspective provides an overview on the development of knowledge related to NAFLD with a focus on landmark findings that have influenced current paradigms and key knowledge gaps that need to be filled to make progress. Specifically, a timeline of scientific discovery of both basic disease mechanisms (with a focus on human data) and the evolution of knowledge about the clinical course of the disease is provided and related to current approaches to treat and eventually prevent NAFLD.

Entities:  

Mesh:

Year:  2019        PMID: 31024089     DOI: 10.1038/s41575-019-0144-8

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  113 in total

Review 1.  Therapeutic pipeline in nonalcoholic steatohepatitis.

Authors:  Raj Vuppalanchi; Mazen Noureddin; Naim Alkhouri; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

Review 2.  LXRα Phosphorylation in Cardiometabolic Disease: Insight From Mouse Models.

Authors:  Maud Voisin; Matthew C Gage; Natalia Becares; Elina Shrestha; Edward A Fisher; Ines Pineda-Torra; Michael J Garabedian
Journal:  Endocrinology       Date:  2020-07-01       Impact factor: 4.736

Review 3.  Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

Authors:  Mehmet Kanbay; Mustafa C Bulbul; Sidar Copur; Baris Afsar; Alan A Sag; Dimitrie Siriopol; Masanari Kuwabara; Silvia Badarau; Adrian Covic; Alberto Ortiz
Journal:  J Nephrol       Date:  2020-05-21       Impact factor: 3.902

4.  Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.

Authors:  Aline de Conti; Volodymyr Tryndyak; Rose A Willett; Barbara Borowa-Mazgaj; Anna Watson; Ralph Patton; Sangeeta Khare; Levan Muskhelishvili; Greg R Olson; Mark I Avigan; Carl E Cerniglia; Sharon A Ross; Arun J Sanyal; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  FASEB J       Date:  2020-04-18       Impact factor: 5.191

Review 5.  Pyruvate Dehydrogenase as a Therapeutic Target for Nonalcoholic Fatty Liver Disease.

Authors:  Christina T Saed; Seyed Amirhossein Tabatabaei Dakhili; John R Ussher
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-03

6.  Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stress.

Authors:  Wan-Jun Zhao; Yang-Ping Bian; Qiu-Hui Wang; Fei Yin; Li Yin; Yong-Lan Zhang; Jian-Hui Liu
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

7.  Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis.

Authors:  Jiaxin Liu; Bo Dong; Lin Yang; Wei Huang; Songqi Tang
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

8.  Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.

Authors:  Santo Colosimo; Federico Ravaioli; Maria L Petroni; Lucia Brodosi; Francesca Marchignoli; Francesca A Barbanti; Anna S Sasdelli; Giulio Marchesini; Loris Pironi
Journal:  Liver Int       Date:  2021-02-10       Impact factor: 5.828

Review 9.  The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome.

Authors:  Stephen Malnick; Yaakov Maor
Journal:  Visc Med       Date:  2020-04-23

10.  Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis.

Authors:  He-Ming Huang; Shi-Jie Fan; Xiao-Ru Zhou; Yan-Jun Liu; Xiao Li; Li-Ping Liao; Jing Huang; Cui-Cui Shi; Liang Yu; Rong Fu; Jian-Gao Fan; Yuan-Yuan Zhang; Cheng Luo; Guang-Ming Li
Journal:  Acta Pharmacol Sin       Date:  2021-08-02       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.